{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T19:26:42Z","timestamp":1775244402201,"version":"3.50.1"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"18","license":[{"start":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>Hemophilia B is a rare, hereditary bleeding disorder characterized by a deficiency in clotting factor IX (FIX). Traditional therapeutic strategies involve an economically and physically burdensome combination of prophylactic and episodic (ie, on-demand) administration of clotting factor concentrates (CFCs). The first gene therapy for hemophilia B, etranacogene dezaparvovec (Hemgenix), was approved by the Food and Drug Administration (FDA) in November 2022, with approval for fidanacogene elaparvovec (Beqvez) following in April 2024, produced by CSL Behring and Pfizer, respectively. This literature review aims to provide an overview of current therapeutic strategies for the treatment of hemophilia B, introducing and focusing on the efficacy and safety of the novel gene therapies etranacogene dezaparvovec and fidanacogene elaparvovec.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Summary<\/jats:title>\n                  <jats:p>Both FDA-approved hemophilia B gene therapies, etranacogene dezaparvovec and fidanacogene elaparvovec, utilize adeno-associated virus (AAV) vectors for delivery of the gene encoding FIX. Each of these medications has a distinct AAV serotype, but they have the same treatment modality, with the goal of curing the disease and reducing or eliminating prophylactic CFC requirements. Despite their different AAV serotypes, both products deliver a functional copy of the gene encoding the Padua variant (variant R338L) of human FIX. Recent clinical trials have demonstrated efficacy in increasing FIX concentrations leading to reduced frequency of spontaneous bleeding episodes; however, safety and response durability remain concerns.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>For the first time in history, individuals with hemophilia B have access to potentially curative therapies through gene therapy. Both etranacogene dezaparvovec and fidanacogene elaparvovec offer significant efficacy, reducing the number of bleeding episodes and raising FIX concentrations with a single lifetime administration. While concerns remain regarding long-term safety and durability, these therapies represent a major advancement in reducing treatment burden and improving quality of life for patients. The future of hemophilia B management now holds the promise of greater independence from frequent prophylactic treatments.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajhp\/zxaf005","type":"journal-article","created":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T05:38:25Z","timestamp":1737956305000},"page":"960-969","source":"Crossref","is-referenced-by-count":7,"title":["Gene-ius at work: Hemophilia B treatment enters a new era"],"prefix":"10.1093","volume":"82","author":[{"given":"Madison W","family":"Northington","sequence":"first","affiliation":[{"name":"Auburn University Harrison College of Pharmacy , Auburn, AL ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah E","family":"Rice","sequence":"additional","affiliation":[{"name":"Auburn University Harrison College of Pharmacy , Auburn, AL ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abigail L","family":"Holmes","sequence":"additional","affiliation":[{"name":"Auburn University Harrison College of Pharmacy , Auburn, AL ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Courtney S","family":"Watts Alexander","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Auburn University Harrison College of Pharmacy , Auburn, AL ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,1,27]]},"reference":[{"key":"2025090819570882100_CIT0001","author":"Centers for Disease Control and Prevention","year":"2024"},{"key":"2025090819570882100_CIT0002","author":"Centers for Disease Control and Prevention","year":"2024"},{"issue":"suppl 6","key":"2025090819570882100_CIT0003","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH Guidelines for the Management of Hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"issue":"5","key":"2025090819570882100_CIT0004","doi-asserted-by":"publisher","first-page":"2762","DOI":"10.3390\/ijms23052762","article-title":"The molecular basis of FIX deficiency in hemophilia B","volume":"23","author":"Shen","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"9","key":"2025090819570882100_CIT0005","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1111\/jth.15793","article-title":"Structural insights into blood coagulation factor VIII: procoagulant complexes, membrane binding, and antibody inhibition","volume":"20","author":"Childers","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"4","key":"2025090819570882100_CIT0006","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1111\/hae.13804","article-title":"Phenotypic characterization of haemophilia B\u2014understanding the underlying biology of coagulation factor IX","volume":"25","author":"Tj\u00e4rnlund-Wolf","year":"2019","journal-title":"Haemophilia"},{"issue":"6","key":"2025090819570882100_CIT0007","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1586\/EHM.09.63","article-title":"Advancements in gene transfer-based therapy for hemophilia A","volume":"2","author":"Doering","year":"2009","journal-title":"Expert Rev Hematol"},{"key":"2025090819570882100_CIT0008","author":"Cleveland Clinic"},{"issue":"suppl 6","key":"2025090819570882100_CIT0009","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/hae.13449","article-title":"Joint disease in haemophilia: pathophysiology, pain and imaging","volume":"24","author":"Vulpen","year":"2018","journal-title":"Haemophilia"},{"key":"2025090819570882100_CIT0010","doi-asserted-by":"publisher","first-page":"897","DOI":"10.2147\/JBM.S325031","article-title":"Integrated hemophilia patient care via a national network of care centers in the United States: a model for rare coagulation disorders","volume":"12","author":"Valentino","year":"2021","journal-title":"J Blood Med"},{"issue":"2","key":"2025090819570882100_CIT0011","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1111\/bjh.17438","article-title":"Viral hepatitis in haemophilia: historical perspective and current management","volume":"195","author":"Isfordink","year":"2021","journal-title":"Br J Haematol"},{"issue":"1","key":"2025090819570882100_CIT0012","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s11420-009-9140-9","article-title":"Musculoskeletal complications of hemophilia","volume":"6","author":"Rodriguez-Merchan","year":"2010","journal-title":"HSS J"},{"issue":"23","key":"2025090819570882100_CIT0013","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1056\/NEJM200106073442307","article-title":"The hemophilias\u2014from royal genes to gene therapy","volume":"344","author":"Mannucci","year":"2001","journal-title":"N Engl J Med"},{"issue":"5","key":"2025090819570882100_CIT0014","doi-asserted-by":"publisher","first-page":"378","DOI":"10.2450\/2019.0253-18","article-title":"Intracranial haemorrhage in children and adults with haemophilia A and B: a literature review of the last 20 years","volume":"17","author":"Zanon","year":"2019","journal-title":"Blood Transfus"},{"issue":"6","key":"2025090819570882100_CIT0015","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1080\/14656566.2023.2196012","article-title":"Current factor IX replacement options for hemophilia B and the challenges ahead","volume":"24","author":"Franchini","year":"2023","journal-title":"Expert Opin Pharmacother"},{"key":"2025090819570882100_CIT0016","author":"Rebinyn","year":"2022"},{"key":"2025090819570882100_CIT0017","author":"Idelvion","year":"2023"},{"key":"2025090819570882100_CIT0018","author":"Alprolix","year":"2024"},{"issue":"4","key":"2025090819570882100_CIT0019","doi-asserted-by":"publisher","first-page":"100195","DOI":"10.1016\/j.rpth.2023.100195","article-title":"Extended half-life factor IX prophylaxis up to every 21 days in hemophilia B: a longitudinal analysis of the efficacy and safety in selected adult patients","volume":"7","author":"Pabinger","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"issue":"1","key":"2025090819570882100_CIT0020","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1080\/03007995.2019.1662675","article-title":"Assessing bleeding rates, related clinical impact and factor utilization in German hemophilia B patients treated with extended half-life rIX-FP compared to prior drug therapy","volume":"36","author":"Oldenburg","year":"2020","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"2025090819570882100_CIT0021","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.1007\/s12325-020-01300-6","article-title":"Real-world utilisation and bleed rates in patients with haemophilia B who switched to recombinant factor IX fusion protein (rIX-FP): a retrospective international analysis","volume":"37","author":"Hermans","year":"2020","journal-title":"Adv Ther"},{"key":"2025090819570882100_CIT0022","author":"National Hemophilia Foundation"},{"issue":"suppl 4","key":"2025090819570882100_CIT0023","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1016\/S0049-3848(08)70029-X","article-title":"Use of albumin fusion technology to prolong the half-life of recombinant factor VIIa","volume":"122","author":"Schulte","year":"2008","journal-title":"Thromb Res"},{"key":"2025090819570882100_CIT0024","author":"Food and Drug Administration","year":"2022"},{"key":"2025090819570882100_CIT0025","author":"Food and Drug Administration","year":"2023"},{"key":"2025090819570882100_CIT0026","author":"Food and Drug Administration","year":"2022"},{"issue":"4","key":"2025090819570882100_CIT0027","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40259-017-0234-5","article-title":"Adeno-associated virus (AAV) as a vector for gene therapy","volume":"31","author":"Naso","year":"2017","journal-title":"BioDrugs"},{"key":"2025090819570882100_CIT0028","author":"Food and Drug Administration","year":"2023"},{"key":"2025090819570882100_CIT0029","author":"Food and Drug Administration","year":"2024"},{"issue":"17","key":"2025090819570882100_CIT0030","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1056\/NEJMoa0904377","article-title":"X-linked thrombophilia with a mutant factor IX (factor IX Padua)","volume":"361","author":"Simioni","year":"2009","journal-title":"N Engl J Med"},{"key":"2025090819570882100_CIT0031","author":"Hemgenix","year":"2022"},{"key":"2025090819570882100_CIT0032","author":"Beqvez","year":"2024"},{"issue":"19","key":"2025090819570882100_CIT0033","doi-asserted-by":"publisher","first-page":"5671","DOI":"10.1182\/bloodadvances.2022008886","article-title":"Stable and durable factor IX levels in hemophilia B patients over 3 years post etranacogene dezaparvovec gene therapy","volume":"7","author":"von Drygalski","year":"2023","journal-title":"Blood Adv"},{"key":"2025090819570882100_CIT0034","article-title":"Dose confirmation trial of AAV5-hFIXco-Padua","author":"CSL Behring","year":"2024"},{"key":"2025090819570882100_CIT0035","article-title":"HOPE-B: trial of AMT-061 in severe or moderately severe hemophilia B patients","author":"CSL Behring","year":"2025"},{"issue":"8","key":"2025090819570882100_CIT0036","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1056\/NEJMoa2211644","article-title":"Gene therapy with etranacogene dezaparvovec for hemophilia B","volume":"388","author":"Pipe","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"2025090819570882100_CIT0037","doi-asserted-by":"publisher","first-page":"e265","DOI":"10.1016\/S2352-3026(24)00006-1","article-title":"Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial","volume":"11","author":"Coppens","year":"2024","journal-title":"Lancet Haematol"},{"issue":"23","key":"2025090819570882100_CIT0038","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1056\/NEJMoa1708538","article-title":"Hemophilia B gene therapy with a high-specific-activity factor IX variant","volume":"377","author":"George","year":"2017","journal-title":"N Engl J Med"},{"key":"2025090819570882100_CIT0039","article-title":"Gene therapy, open-label, dose-escalation study of PF-06838435 (SPK-9001) [adeno-associated viral vector with human factor IX gene] in subjects with hemophilia B","author":"Pfizer","year":"2020"},{"key":"2025090819570882100_CIT0040","article-title":"Phase 3, open-label, single-arm study to evaluate efficacy and safety of FIX gene transfer with PF-06838435 (rAAV-Spark100-hFIX-R338L) in adult male participants with moderately severe to severe hemophilia B (FIX:C = 2%) (BeneGene-2)","author":"Pfizer","year":"2024"},{"key":"2025090819570882100_CIT0041","volume-title":"Fidanacogene Elaparvovec (Beqvez): CADTH Reimbursement Recommendation","author":"Canadian Agency for Drugs and Technologies in Health","year":"2024"},{"issue":"3","key":"2025090819570882100_CIT0042","doi-asserted-by":"publisher","first-page":"316","DOI":"10.18553\/jmcp.2021.27.3.316","article-title":"Health care resource utilization and costs among adult patients with hemophilia A on factor VIII prophylaxis: an administrative claims analysis","volume":"27","author":"Croteau","year":"2021","journal-title":"J Manag Care Spec Pharm"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxaf005\/61642975\/zxaf005.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/82\/18\/960\/61642975\/zxaf005.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/82\/18\/960\/61642975\/zxaf005.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T23:57:21Z","timestamp":1757375841000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/82\/18\/960\/7983887"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,27]]},"references-count":42,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2025,1,27]]},"published-print":{"date-parts":[[2025,9,9]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxaf005","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9,15]]},"published":{"date-parts":[[2025,1,27]]}}}